Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2014 by Mayo Clinic.
Recruitment status was  Active, not recruiting
Tapimmune Inc.
Information provided by (Responsible Party):
Keith Knutson, Ph.D., Mayo Clinic Identifier:
First received: June 28, 2012
Last updated: April 8, 2014
Last verified: April 2014
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)